Gnostormon (Colecalciferol)

Gnostormon is indicated for conditions where vitamin D levels are insufficient or where calcium metabolism needs support.

• Correction of documented vitamin D deficiency confirmed by serum 25‑hydroxyvitamin D testing.
• Supplementation in individuals with low calcium intake to improve calcium absorption and balance.
• Help maintain normal bone mineral density and reduce risk of bone demineralization in adults.
• Support skeletal health and reduce fracture risk in older adults with age‑related bone loss.
• Used as an adjunct in the management of osteomalacia or rickets when prescribed by a healthcare professional.

The safety profile of colecalciferol, the active ingredient in Gnostormon, reflects the typical effects observed with vitamin D supplementation.

Common

• Mild gastrointestinal discomfort such as nausea or abdominal cramps.
• Transient headache or dizziness, especially after initiating therapy.
• Slight increase in serum calcium levels that usually remains within normal limits.
• Dry mouth or mild metallic taste, which usually resolves without intervention.

Serious

• Hypercalcemia presenting with excessive thirst, frequent urination, or kidney stones.
• Allergic reactions including rash, itching, or swelling of the face and throat.
• Severe hypercalcemia leading to cardiac arrhythmias or confusion (rare).
• Calcification of soft tissues such as blood vessels in cases of prolonged excess intake.

When using Gnostormon, certain precautions should be observed to ensure safe and effective supplementation.

• Assess baseline serum 25‑hydroxyvitamin D and calcium levels before starting therapy.
• Adjust dose in individuals with renal impairment or a history of hypercalcemia.
• Avoid use in patients with known hypersensitivity to colecalciferol or any excipients.
• Monitor calcium status periodically during long‑term use, especially in the elderly.
• Keep out of reach of children; accidental ingestion of high doses can cause toxicity.
• Do not exceed the recommended daily allowance without medical supervision.

Colecalciferol may interact with certain medications, influencing either vitamin D metabolism or calcium balance.

Avoid

• Thiazide diuretics, which can increase calcium reabsorption and raise the risk of hypercalcemia.
• Vitamin K antagonists (e.g., warfarin), where high vitamin D levels may enhance anticoagulant effects.
• Lithium therapy, as vitamin D excess may affect lithium levels and renal function.

Use with caution

• Calcium supplements or antacids containing calcium, as combined use may lead to excessive calcium levels.
• Corticosteroids, which can reduce vitamin D activation and may require dose adjustment.
• Orlistat, which can impair the absorption of fat‑soluble vitamins including vitamin D.
• Bisphosphonates, where concurrent high vitamin D may increase risk of hypercalcemia after infusion.